Firebrick Pharma Limited (ASX:FRE)

Market Cap	16.98M
Revenue (ttm)	515.51K
Net Income (ttm)	-2.63M
Shares Out	249.72M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,012
Average Volume	67,956
Open	0.0690
Previous Close	0.0650
Day's Range	0.0680 - 0.0690
52-Week Range	0.0510 - 0.1000
Beta	1.36
RSI	41.01
Earnings Date	Aug 29, 2025

About Firebrick Pharma

Firebrick Pharma Limited engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia. The company offers broad-spectrum antimicrobial nasal spray for the treatment of common cold under the Nasodine name. It also operates in the United states and Singapore. Firebrick Pharma Limited was incorporated in 2012 and is based in Melbourne, Australia.

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: FRE

Financial Performance

In 2025, Firebrick Pharma's revenue was 515,507, a decrease of -81.26% compared to the previous year's 2.75 million. Losses were -2.63 million, 124.0% more than in 2024.